Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double‐blind, placebo‐controlled trial
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This was a flexible-dosed study to evaluate the efficacy and safety of duloxetine 30-120 mg once daily in the treatment of generalized anxiety disorder (GAD) in older adult patients. METHODS: Patients with GAD, who were at least 65 years of age, were randomly assigned to double-blind treatment with either duloxetine (N = 151) or placebo (N = 140). The primary efficacy measure was the Hamilton Anxiety Rating Scale (HAM-A) total score, and the primary endpoint was at week 10. Global functioning was assessed by the Sheehan Disability Scale (SDS). Safety and tolerability was assessed by the occurrence of treatment-emergent adverse events, serious adverse events, laboratory analyses, and vital signs. Analyses were conducted on an intent-to-treat basis. RESULTS: The overall baseline mean HAM-A total score was 24, and SDS global score was 14. Completion rates were 75% for placebo and 76% for duloxetine. At week 10, duloxetine was superior to placebo on mean changes from baseline in HAM-A total scores (-15.9 vs. -11.7, p < 0.001) and in SDS global scores (-8.6 vs. -5.4, p < 0.001). Treatment-emergent adverse events occurred in ≥5% of duloxetine-treated patients and twice the rate than with placebo including constipation (9% vs. 4%, p = 0.06), dry mouth (7% vs. 1%, p = 0.02), and somnolence (6% vs. 2%, p = 0.14). CONCLUSION: Duloxetine treatment was efficacious in the improvement of anxiety and functioning in older adult patients with GAD, and the safety profile was consistent with previous GAD studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 2×
“Treatment-emergent suicidal ideation assessed by the Columbia Suicide Severity Rating Scale was reported for nine patients, five (3.8”
MethodInfluentialThe size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754 · cited 2×
“4% for GAD in persons >65 years of age (Wittchen et al., 2011).”
BackgroundInfluentialSheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Shear, M. K., Vander Bilt, J., Rucci, P., Endicott, J., Lydiard, B., Otto, M. W., Pollack, M. H., Chandler, L., Williams, J., Ali, A., et al. (2001) · Depression and Anxiety · doi:10.1002/da.1033 · Cited by 483
Bandelow, B., Sher, L., Bunevicius, R., Hollander, E., Kasper, S., Zohar, J., Möller, H.-J., WFSBP Task Force on Mental Disorders in Primary Care, & WFSBP Task Force on Anxiety Disorders, O. A. P. (2012) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2012.667114 · Cited by 428 · cited 2×
“…the neurobiology of GAD, pharmacological guidelines recommend treatment with selective serotonin reuptake inhibitors, selective serotonin– norepinephrine reuptake inhibitors, or pregablin (Montgomery et al., 2006; Hoffman and Mathew, 2008; Baldwin et al., 2012; Bandelow et al., 2012).”
BackgroundRaskin, J., Wiltse, C. G., Siegal, A., Sheikh, J., Xu, J., Dinkel, J. J., Rotz, B. T., & Mohs, R. C. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.900 · Cited by 329
Interventions for generalized anxiety disorder in older adults: Systematic review and meta-analysis
Gonçalves, D. C., & Byrne, G. J. (2012) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2011.08.010 · Cited by 227 · cited 1×
“At week 10, duloxetine was superior to placebo on mean changes from baseline in HAM-A total scores ( 15.9 vs. 11.7, p 0.001) and in SDS global scores ( 8.6 vs. 5.4, p 0.001).”
BackgroundInfluentialAllgulander, C., Hackett, D., & Salinas, E. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.1.15 · Cited by 175 · cited 2×
“Approved serotonin–norepinephrine reuptake inhibitors include duloxetine (Hartford et al., 2007; Koponen et al., 2007; Rynn et al., 2008; Nicolini et al., 2009) and venlafaxine (Davidson et al., 1999; Gelenberg et al., 2000; Rickels et al., 2000; Allgulander et al., 2001; Katz et al., 2002).”
BackgroundAnxiety disorders: a comprehensive review of pharmacotherapies
Hoffman, E. J., & Mathew, S. J. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20041 · Cited by 149 · cited 9×
“It was only after the week 2 visit that duloxetine could be increased to 60mg. Patients treated with duloxetine also demonstrated superior improvement over placebo-treated patients in each of the disease-specific secondary measures, as well as in global functioning, quality of life, and the patients’ impression of fee…”
MethodInfluentialAge at onset of generalized anxiety disorder in older adults
Le Roux, H., Gatz, M., & Wetherell, J. L. (2005) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200501000-00005 · Cited by 104
Cited by
Strawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., & Levine, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1491966 · Cited by 214
“Duloxetine has been evaluated in older adults with GAD and, in this double-blind, placebo-controlled study, adults aged 65 years or older were randomized to duloxetine (N = 151) or placebo (N = 140) and, over the course of 10 weeks of treatment, reductions in HAM-A total scores were significantly greater than those in…”
BackgroundMethodSelf-citationCarl, E., Witcraft, S. M., Kauffman, B. Y., Gillespie, E. M., Becker, E. S., Cuijpers, P., Van Ameringen, M., Smits, J. A. J., & Powers, M. B. (2020) · Cognitive Behaviour Therapy · doi:10.1080/16506073.2018.1560358 · Cited by 151
Gomez, A. F., Barthel, A. L., & Hofmann, S. G. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1472767 · Cited by 125
Meta-analysis: Risk of dry mouth with second generation antidepressants
Cappetta, K., Beyer, C., Johnson, J. A., & Bloch, M. H. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.12.012 · Cited by 49
Antidepressants versus placebo for generalised anxiety disorder (GAD)
Kopcalic, K., Arcaro, J., Pinto, A., Ali, S., Barbui, C., Curatoli, C., Martin, J., & Guaiana, G. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012942.pub2 · Cited by 16
Metadata
- Authors
- Alaka, K. J., Noble, W., Montejo, A., Dueñas, H., Munshi, A., Strawn, J. R., Lenox‐Smith, A., Ahl, J., Bidzan, L., Dorn, B., & Ball, S.
- Venue
- International Journal of Geriatric Psychiatry
- Publisher
- Wiley
- Published
- 2014-02-20
- Volume
- 29
- Issue
- 9
- Pages
- 978-986
- ISSN
- 0885-6230 (ISSN-L)
- 1099-1166
- OpenAlex
- W1570196813
- Cited by
- 45
- References
- 11
- FWCI
- 3.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double‐blind, placebo‐controlled trial. https://app.cochat.ai/papers/10.1002/gps.4088
- The paper
- Alaka, K. J., Noble, W., Montejo, A., Dueñas, H., Munshi, A., Strawn, J. R., Lenox‐Smith, A., Ahl, J., Bidzan, L., Dorn, B., & Ball, S. (2014). Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double‐blind, placebo‐controlled trial. International Journal of Geriatric Psychiatry. https://doi.org/10.1002/gps.4088
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.